oleksandr-halushchak-shutterstock-com

OLEKSANDR HALUSHCHAK / SHUTTERSTOCK.COM

10 October 2016Biotechnology

A woolly debate: the rights and wrongs of cloning

“Should life be patented?” asks Paul Chapman, head of Avidity’s life sciences team, relaying the concern of the UK public and intellectual property officials when the creators of Dolly the Sheep sought to patent their experiment.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Attorney v examiner: Navigating patenting's AI tools ‘arms race’

Panitch Schwarze brings in molecular biologist

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

Most active firms at UPC revealed in report on court’s first year

FTC supports USPTO terminal disclaimer plan amid opposition

Labour govt appoints new Minister with IP oversight